📰 Nasdaq Ctxr News
Nasdaq Ctxr News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Ctxr. Real-time updates on events, politics, business and more.
November 1, 2023
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Get Free Report) was the recipient of a significant decrease in short interest in October. As of October 15th, there was short interest totalling 17,210,000 shares, a decrease of 7.2% from the September 30th total of 18,540,000 shares. Based on an average daily trading volume, of 997,100 shares, the days-to-cover […]
August 3, 2023
Citius Pharmaceuticals (NASDAQ:CTXR – Get Free Report) had its target price decreased by research analysts at HC Wainwright from $6.00 to $4.00 in a research note issued on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 337.59% from the company’s […]
June 19, 2023
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Get Rating) was the recipient of a large increase in short interest in May. As of May 31st, there was short interest totalling 13,760,000 shares, an increase of 13.4% from the May 15th total of 12,130,000 shares. Based on an average daily volume of 1,450,000 shares, the short-interest ratio is […]
June 3, 2023
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Get Rating) – Investment analysts at HC Wainwright decreased their Q3 2023 earnings per share estimates for Citius Pharmaceuticals in a report issued on Tuesday, May 30th. HC Wainwright analyst V. Bernardino now forecasts that the company will earn ($0.07) per share for the quarter, down from their previous estimate […]
May 17, 2023
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Get Rating) was the target of a large growth in short interest in April. As of April 30th, there was short interest totalling 13,600,000 shares, a growth of 6.7% from the April 15th total of 12,750,000 shares. Based on an average trading volume of 953,100 shares, the short-interest ratio is […]
May 4, 2023
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Get Rating) was the target of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 12,750,000 shares, an increase of 6.5% from the March 31st total of 11,970,000 shares. Approximately 9.5% of the shares of the company are short […]
April 2, 2023
HC Wainwright reaffirmed their buy rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR – Get Rating) in a research note issued to investors on Wednesday morning, Benzinga reports. HC Wainwright currently has a $6.00 price target on the stock. HC Wainwright also issued estimates for Citius Pharmaceuticals’ Q2 2023 earnings at ($0.05) EPS, Q3 2023 earnings […]
March 31, 2023
Citius Pharmaceuticals (NASDAQ:CTXR – Get Rating)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They currently have a $6.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 412.82% from the company’s current price. […]
June 3, 2022
Wall Street brokerages expect Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Get Rating) to report earnings per share of ($0.05) for the current quarter, according to Zacks. Zero analysts have made estimates for Citius Pharmaceuticals’ earnings. The highest EPS estimate is ($0.03) and the lowest is ($0.07). Citius Pharmaceuticals also posted earnings of ($0.05) per share in […]
March 31, 2022
Zacks Investment Research upgraded shares of Citius Pharmaceuticals (NASDAQ:CTXR – Get Rating) from a sell rating to a hold rating in a research report report published on Wednesday morning, Zacks.com reports. According to Zacks, “Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical […]